Market Spotlight: Ischemic Stroke
Market Spotlight: Ischemic Stroke
$1,318.00
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2020, there were approximately 81.6 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 87.5 million prevalent cases by 2029.
- The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with two drugs administered intravenously and one drug administered subcutaneously.
- The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II. Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.
- High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for S-005151, topline Phase IIb trial results for ReN001, topline Phase III trial results for Cirara, and an expected supplemental CHMP opinion for Brilinta.
- The overall likelihood of approval of a Phase I ischemic stroke asset is 0.8%, and the average probability a drug advances from Phase III is 11.1%. Drugs, on average, take 13.3 years from Phase I to approval, compared to 10.1 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I–II, and 30% in Phase III–IV.
- The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the stroke space is dominated by completed trials. Roche has the highest number of completed clinical trials for stroke, with 22 trials.
- Boehringer Ingelheim and Roche lead industry sponsors with the highest overall number of clinical trials for stroke.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Acute treatment of ischemic stroke
11 Long-term treatments
11 Palliative care
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 LT3001 for Ischemic Stroke (August 3, 2021)
27 TMS-007 for Ischemic Stroke (May 12, 2021)
29 SB623 for Ischemic Stroke (September 14, 2020)
31 DM199 for Ischemic Stroke (May 13, 2020)
33 NA-1 for Ischemic Stroke (February 20, 2020)
36 KEY UPCOMING EVENTS
37 KEY REGULATORY EVENTS
37 Further Horizons For Direct Oral Anticoagulants
38 PROBABILITY OF SUCCESS
39 LICENSING AND ASSET ACQUISITION DEALS
39 Biogen Deals With Ginkgo, Capsigen, Envisagenics, TMS
40 REVENUE OPPORTUNITY
41 CLINICAL TRIAL LANDSCAPE
42 Sponsors by status
43 Sponsors by phase
45 BIBLIOGRAPHY
46 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in prevalent cases of ischemic stroke, 2020–29
19 Figure 2: Overview of pipeline drugs for ischemic stroke in the US
20 Figure 3: Pipeline drugs for ischemic stroke, by company
20 Figure 4: Pipeline drugs for ischemic stroke, by drug type
20 Figure 5: Pipeline drugs for ischemic stroke, by classification
27 Figure 6: LT3001 for Ischemic Stroke (August 3, 2021): Phase IIa – 201
29 Figure 7: TMS-007 for Ischemic Stroke (May 12, 2021): Phase IIa – Single IV Administration (JP)
31 Figure 8: SB623 for Ischemic Stroke (September 14, 2020): Phase IIb – ACTIsSIMA
33 Figure 9: DM199 for Ischemic Stroke (May 13, 2020): Phase II – ReMEDy
35 Figure 10: NA-1 for Ischemic Stroke (February 20, 2020): Phase III – ESCAPE-NA1
36 Figure 11: Key upcoming events in ischemic stroke
38 Figure 12: Probability of success in the ischemic stroke pipeline
41 Figure 13: Clinical trials in stroke
41 Figure 14: Top 10 drugs for clinical trials in stroke
42 Figure 15: Top 10 companies for clinical trials in stroke
42 Figure 16: Trial locations in stroke
43 Figure 17: Stroke trials status
44 Figure 18: Stroke trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of ischemic stroke, 2020–29
17 Table 2: Marketed drugs for ischemic stroke
22 Table 3: Pipeline drugs for ischemic stroke in the US
26 Table 4: LT3001 for Ischemic Stroke (August 3, 2021)
28 Table 5: TMS-007 for Ischemic Stroke (May 12, 2021)
30 Table 6: SB623 for Ischemic Stroke (September 14, 2020)
32 Table 7: DM199 for Ischemic Stroke (May 13, 2020)
34 Table 8: NA-1 for Ischemic Stroke (February 20, 2020)
40 Table 9: Historical global sales, by drug ($m), 2016–20
40 Table 10: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Gout 
Sign up to the